Latest Information Update: 16 Jul 2016
At a glance
- Originator Pfizer
- Developer Ziarco
- Mechanism of Action Histamine H3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-rhinitis in United Kingdom (PO)
- 05 Nov 2012 Preclinical trials in Allergic rhinitis in United Kingdom (PO)